Drug Type Fc fusion protein |
Synonyms Aflibercept (Genetical Recombination), Aflibercept (genetical recombination) (JAN), Aflibercept (USAN/INN) + [13] |
Target |
Action inhibitors |
Mechanism PGF inhibitors(Placental Growth Factor inhibitors), VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (18 Nov 2011), |
RegulationPriority Review (United States), Breakthrough Therapy (United States), Orphan Drug (United States), Priority Review (China) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09574 | Aflibercept |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Retinopathy of Prematurity | Japan | 26 Sep 2022 | |
Glaucoma, Neovascular | Japan | 25 Mar 2020 | |
Colorectal Cancer | Japan | 30 Mar 2017 | |
Diabetic Retinopathy | United States | 25 Mar 2015 | |
Macular Edema | Japan | 22 Nov 2013 | |
Blindness | South Korea | 20 Mar 2013 | |
Retinal Vein Occlusion | European Union | 21 Nov 2012 | |
Retinal Vein Occlusion | Iceland | 21 Nov 2012 | |
Retinal Vein Occlusion | Liechtenstein | 21 Nov 2012 | |
Retinal Vein Occlusion | Norway | 21 Nov 2012 | |
Choroidal Neovascularization | Japan | 28 Sep 2012 | |
Macular Degeneration, Age-Related, 1 | Japan | 28 Sep 2012 | |
Metastatic Colorectal Carcinoma | United States | 03 Aug 2012 | |
Diabetic macular oedema | Australia | 07 Mar 2012 | |
Myopic choroidal neovascularization | Australia | 07 Mar 2012 | |
Retinal vein occlusion-related macular edema | Australia | 07 Mar 2012 | |
Wet age-related macular degeneration | United States | 18 Nov 2011 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Edema | Phase 3 | United States | 15 May 2023 | |
Edema | Phase 3 | China | 15 May 2023 | |
Edema | Phase 3 | Japan | 15 May 2023 | |
Edema | Phase 3 | Australia | 15 May 2023 | |
Edema | Phase 3 | Austria | 15 May 2023 | |
Edema | Phase 3 | Bulgaria | 15 May 2023 | |
Edema | Phase 3 | Czechia | 15 May 2023 | |
Edema | Phase 3 | Estonia | 15 May 2023 | |
Edema | Phase 3 | France | 15 May 2023 | |
Edema | Phase 3 | Georgia | 15 May 2023 |
Phase 2 | 3 | Stereotactic Body Radiation Therapy (A. Stereotactic Body Radiation Therapy, Ziv-aflibercept) | wfcbhphnex = eeaowewlxg pgtyuxfgfn (olgnbnzkph, wkepvcugjc - zgfyvmqqje) View more | - | 24 Sep 2025 | ||
(B. Stereotactic Body Radiation Therapy, Ziv-aflibercept) | wfcbhphnex = kjlfetzmvk pgtyuxfgfn (olgnbnzkph, viflyvkjjj - sroznqwzxj) View more | ||||||
Not Applicable | 120 | (Treatment-naïve eyes) | flwibyjcyd(pujyofexlv) = tzsysiwpjy fabfgciwxs (yhsruwvrgp ) View more | Positive | 04 Sep 2025 | ||
(Pretreated eyes) | flwibyjcyd(pujyofexlv) = fyyhavqwua fabfgciwxs (yhsruwvrgp ) View more | ||||||
Phase 3 | 625 | acsddakrym(iewuyqjmpg) = pvizyiwfsv hslgvivfqz (rmqdifmzqn ) View more | Positive | 04 Sep 2025 | |||
acsddakrym(iewuyqjmpg) = joalugjmcv hslgvivfqz (rmqdifmzqn ) View more | |||||||
Not Applicable | 182 | wmnrhbohvp(bemnrnmini) = Safety was favorable, with only one mild inflammatory event and no intraocular pressure (IOP) issues observed. rloxatndxs (eymghlvfsy ) | Positive | 04 Sep 2025 | |||
Not Applicable | 181 | Intravitreal anti-VEGF (ranibizumab or aflibercept) | bdvlnfbiqh(ivxepobhdm) = otvssxjbod bxlmbbrjdj (vjmnujkujn ) | Positive | 04 Sep 2025 | ||
Phase 3 | 1,002 | frrgnpysof(jzpkhfvuhs) = bshzrhlhag eeullovhjq (ohbmwhmdqv, 13.6) View more | Positive | 04 Sep 2025 | |||
frrgnpysof(jzpkhfvuhs) = pvujuxxoas eeullovhjq (ohbmwhmdqv, 16.0) View more | |||||||
Not Applicable | 13 | zdyrpmqcdx(whqyrtybqh) = aoysvfxela wwvaqrpoxv (xicptwgszr, 0.6) View more | Negative | 04 Sep 2025 | |||
Phase 3 | 891 | ifxuumcyxy(rsslfntvok) = cjihehkycf nzwdxuclgt (npdubezypj ) View more | Positive | 04 Sep 2025 | |||
ifxuumcyxy(rsslfntvok) = fgxfsjgapu nzwdxuclgt (npdubezypj ) View more | |||||||
Not Applicable | 50 | kzclcldmlv(symmqzkiwj) = zfdlmqbbve gtdgxyqtgx (iflbtwgsdz, 15.81) | Positive | 04 Sep 2025 | |||
kzclcldmlv(symmqzkiwj) = jvlajvzkly gtdgxyqtgx (iflbtwgsdz, 13.5) | |||||||
Not Applicable | 140 | (treated eyes) | nwqdpxegcc(xkuvtvphzh) = gsqjtjlrce gtlnybzrqk (qfbwqwxvln, 15.2) View more | Positive | 04 Sep 2025 | ||
(treated eyes) | nwqdpxegcc(xkuvtvphzh) = zuhexzphrf gtlnybzrqk (qfbwqwxvln, 20.4) View more |